Record Information |
---|
Version | 2.0 |
---|
Creation Date | 2009-07-30 17:58:43 UTC |
---|
Update Date | 2014-12-24 20:26:07 UTC |
---|
Accession Number | T3D3487 |
---|
Identification |
---|
Common Name | Brimonidine |
---|
Class | Small Molecule |
---|
Description | Brimonidine is only found in individuals that have used or taken this drug. It is a drug used to treat glaucoma. It acts via decreasing aqueous humor synthesis. [Wikipedia] A topical gel formulation, marketed under the name Mirvaso, was FDA approved on August 2013 for the treatment of rosacea. Brimonidine is an alpha adrenergic receptor agonist (primarily alpha-2). It has a peak ocular hypotensive effect occurring at two hours post-dosing. Fluorophotometric studies in animals and humans suggest that Brimonidine has a dual mechanism of action by reducing aqueous humor production and increasing uveoscleral outflow. |
---|
Compound Type | - Adrenergic alpha-2 Receptor Agonist
- Adrenergic alpha-Agonist
- Amide
- Amine
- Antihypertensive Agent
- Bromide Compound
- Drug
- EENT Preparation
- Metabolite
- Organic Compound
- Organobromide
- Synthetic Compound
|
---|
Chemical Structure | |
---|
Synonyms | Synonym | 5-Bromo-6-(2-imidazolin-2-ylamino)quinoxaline | Alphagan | Brimonidina | Brimonidine tartrate | Brimonidinum | Bromoxidine | Mirvaso |
|
---|
Chemical Formula | C11H10BrN5 |
---|
Average Molecular Mass | 292.135 g/mol |
---|
Monoisotopic Mass | 291.012 g/mol |
---|
CAS Registry Number | 59803-98-4 |
---|
IUPAC Name | 5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine |
---|
Traditional Name | brimonidine |
---|
SMILES | BrC1=C(NC2=NCCN2)C=CC2=C1N=CC=N2 |
---|
InChI Identifier | InChI=1S/C11H10BrN5/c12-9-7(17-11-15-5-6-16-11)1-2-8-10(9)14-4-3-13-8/h1-4H,5-6H2,(H2,15,16,17) |
---|
InChI Key | InChIKey=XYLJNLCSTIOKRM-UHFFFAOYSA-N |
---|
Chemical Taxonomy |
---|
Description | belongs to the class of organic compounds known as quinoxalines. Quinoxalines are compounds containing a quinoxaline moiety, a bicyclic heterocycle made up of a benzene ring fused to a pyrazine ring. |
---|
Kingdom | Organic compounds |
---|
Super Class | Organoheterocyclic compounds |
---|
Class | Diazanaphthalenes |
---|
Sub Class | Benzodiazines |
---|
Direct Parent | Quinoxalines |
---|
Alternative Parents | |
---|
Substituents | - Quinoxaline
- Aryl bromide
- Aryl halide
- Pyrazine
- Benzenoid
- 2-imidazoline
- Heteroaromatic compound
- Guanidine
- Azacycle
- Carboximidamide
- Propargyl-type 1,3-dipolar organic compound
- Organic 1,3-dipolar compound
- Organic nitrogen compound
- Hydrocarbon derivative
- Organonitrogen compound
- Organobromide
- Organohalogen compound
- Organopnictogen compound
- Aromatic heteropolycyclic compound
|
---|
Molecular Framework | Aromatic heteropolycyclic compounds |
---|
External Descriptors | |
---|
Biological Properties |
---|
Status | Detected and Not Quantified |
---|
Origin | Exogenous |
---|
Cellular Locations | - Cytoplasm
- Extracellular
- Membrane
|
---|
Biofluid Locations | Not Available |
---|
Tissue Locations | Not Available |
---|
Pathways | Not Available |
---|
Applications | |
---|
Biological Roles | |
---|
Chemical Roles | Not Available |
---|
Physical Properties |
---|
State | Solid |
---|
Appearance | White powder. |
---|
Experimental Properties | Property | Value |
---|
Melting Point | 207.5°C | Boiling Point | Not Available | Solubility | Soluble (1.5 mg/mL) | LogP | 1.7 |
|
---|
Predicted Properties | |
---|
Spectra |
---|
Spectra | Spectrum Type | Description | Splash Key | Deposition Date | View |
---|
Predicted GC-MS | Predicted GC-MS Spectrum - GC-MS (Non-derivatized) - 70eV, Positive | splash10-03xr-0190000000-cd1ec9d5bf9d24fab607 | 2017-09-01 | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | View Spectrum | LC-MS/MS | LC-MS/MS Spectrum - , positive | splash10-0006-0190000000-49c10e93a1977cbe01da | 2017-09-14 | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 10V, Positive | splash10-0006-0090000000-2f188927245c7fb3c618 | 2016-08-03 | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 20V, Positive | splash10-0006-1090000000-fdfdc04ca6c5f2b62c3e | 2016-08-03 | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 40V, Positive | splash10-014i-9030000000-2d727aeec5962a767e61 | 2016-08-03 | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 10V, Negative | splash10-0006-0090000000-91069ec802c3a06026d7 | 2016-08-03 | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 20V, Negative | splash10-0006-0090000000-7bd1085ed4367b683e29 | 2016-08-03 | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 40V, Negative | splash10-0002-2290000000-6351edb1d68a299dfd2d | 2016-08-03 | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 10V, Positive | splash10-0006-0090000000-5f6f82bdb9f8c51818c9 | 2021-09-22 | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 20V, Positive | splash10-0006-0090000000-5f6f82bdb9f8c51818c9 | 2021-09-22 | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 40V, Positive | splash10-000f-0490000000-2720653740ec8305f05d | 2021-09-22 | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 10V, Negative | splash10-0006-0090000000-ffef408a4fb5db76cb85 | 2021-09-23 | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 20V, Negative | splash10-0006-1090000000-0b1325c866472eaa216a | 2021-09-23 | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 40V, Negative | splash10-0f9j-3690000000-b5ba2dea82c37975ad75 | 2021-09-23 | View Spectrum |
|
---|
Toxicity Profile |
---|
Route of Exposure | Minimal systemic absorption occurs after ocular insertion. When the topical gel was applied to adult patients with facial erythema associated with rosacea, the plasma maximum concentration (Cmax) and area under the concentration-time curve (AUC) were 46 ± 62 pg/mL and 417 ± 264 pg.hr/mL, respectively. These values were reached on Day 15 of treatment. |
---|
Mechanism of Toxicity | Brimonidine is an alpha adrenergic receptor agonist (primarily alpha-2). It has a peak ocular hypotensive effect occurring at two hours post-dosing. Fluorophotometric studies in animals and humans suggest that Brimonidine has a dual mechanism of action by reducing aqueous humor production and increasing uveoscleral outflow. The topical gel reduces erythema through direct vasocontriction. |
---|
Metabolism | Metabolized primarily by the liver.
Route of Elimination: Urinary excretion is the major route of elimination of the drug and its metabolites.
Half Life: 2 hours [ophthalmic solution] |
---|
Toxicity Values | LD50: 50 mg/kg (oral, mice)
LD50: 100 mg/kg (oral, rat) |
---|
Lethal Dose | Not Available |
---|
Carcinogenicity (IARC Classification) | No indication of carcinogenicity to humans (not listed by IARC). |
---|
Uses/Sources | The ophthalmic solution is indicated for patients with open-angle glaucoma or ocular hypertension to lower intraocular pressure. The topical gel is indicated for the treatment of persistent (nontransient) facial erythema of rosacea in adults 18 years or older. |
---|
Minimum Risk Level | Not Available |
---|
Health Effects | Not Available |
---|
Symptoms | Oral LD50 is 50 mg/kg in mice and 100 mg/kg in rats. |
---|
Treatment | Not Available |
---|
Normal Concentrations |
---|
| Not Available |
---|
Abnormal Concentrations |
---|
| Not Available |
---|
External Links |
---|
DrugBank ID | DB00484 |
---|
HMDB ID | HMDB14627 |
---|
PubChem Compound ID | 2435 |
---|
ChEMBL ID | CHEMBL844 |
---|
ChemSpider ID | 2341 |
---|
KEGG ID | C07886 |
---|
UniProt ID | Not Available |
---|
OMIM ID | |
---|
ChEBI ID | 3175 |
---|
BioCyc ID | Not Available |
---|
CTD ID | Not Available |
---|
Stitch ID | Brimonidine |
---|
PDB ID | Not Available |
---|
ACToR ID | Not Available |
---|
Wikipedia Link | Brimonidine |
---|
References |
---|
Synthesis Reference | Not Available |
---|
MSDS | Link |
---|
General References | - FDA label
- Drugs.com [Link]
|
---|
Gene Regulation |
---|
Up-Regulated Genes | Not Available |
---|
Down-Regulated Genes | Not Available |
---|